Barter - Figure 12 - Primary endpoint in ILLUMINATE Text

Unfortunately, however, despite the beneficial effects of torcetrapib on the lipids in ILLUMINATE, there were serious adverse effects. As shown in the Kaplan-Meier plot in the Figure, the 2 “time to first major cardiovascular (CV) event”-free curves diverge, but unfortunately in the wrong direction. There was a hazard ratio of 1.25 (p<0.001), meaning a 25% increased risk with torcetrapib versus that in placebo.

Barter P. J Clin Lipidol. 2011; 5(6).